Dementia and Alzheimer Disease

ProMIS Neurosciences reported no cases of ARIA-E in a six-month blinded interim analysis of PMN310, an oligomer-selective antibody in the phase 1b PRECISE-AD trial for Alzheimer disease, alongside early biomarker signals consistent with target engagement.

Phase 1b data published in Nature Medicine and presented at AAIC 2026 showed target engagement and reductions in select cerebrospinal fluid biomarkers of neuronal and synaptic injury with the investigational anti-PD-L1 antibody.

Extended follow-up and new AAIC 2026 data show that tazbentetol, a first-in-class oral synaptic regenerative therapy, produced rapid and durable improvement in cognition and EEG biomarkers in patients with mild-to-moderate Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

A 12-week, placebo-controlled phase 2 trial found that an oral THC/CBD combination significantly reduced agitation in hospice-eligible patients with Alzheimer disease and other dementias, meeting its primary and key secondary endpoints.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 24, 2026.

Stephen Williams, PhD, chief scientific officer of Alamar Biosciences, discusses the potential of eMTBR-tau measurement, multiplex biomarker testing, and AI-driven approaches to improve the characterization of Alzheimer disease and its coexisting pathologies.

Kristen Harris, MD, Medical Director of the Extended Recovery Unit at Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed new findings on functional recovery and community discharge rates in acquired brain injury patients undergoing skilled nursing facility rehabilitation.

Ahead of World Brain Day, NeurologyLive explores 5 emerging strategies for preventing neurologic disease, from modifiable dementia risk factors to GLP-1 drugs, sleep science, the gut brain axis, and wearable technology.

From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.

From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.

Laura Nisenbaum, PhD, Interim Chief Science Officer at the Alzheimer's Drug Discovery Foundation, shares her perspective on the FDA's approval of a subcutaneous starting dose for lecanemab and what it means for access, clinical practice, and the future of Alzheimer disease treatment.

The $100 million PROTECT-Cog trial will test whether adding a GLP-1 drug to the proven U.S. POINTER lifestyle intervention further cuts dementia risk in at-risk older adults.

PrevenTRON, a study of trontinemab, will enroll 1600 cognitively unimpaired participants identified by elevated plasma p-tau217, using time to clinical progression as the primary endpoint.

SAR448851 showed favorable safety, high CNS penetration, and up to 50% reductions in CSF soluble TREM2 in phase 1, supporting the design of TREMHANCE, a phase 2 trial now in final planning with p-tau217 as its primary endpoint.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 17, 2026.

The global phase 3 registration trial enrolled 1535 patients across 240 sites and has completed its 52-week double-blind treatment phase, with no unexpected safety signals observed, even in participants on concomitant antiamyloid therapies.

Across 3 first-in-human studies in healthy volunteers and cognitively impaired adults, MK-2214 demonstrated dose-proportional pharmacokinetics, an approximately 80-day half-life, and near-complete suppression of free pS413 tau in CSF at doses of 20 mg and above.

The assistant professor in the Department of Behavioral Science at the University of Kentucky discusses a nonpharmacologic intervention designed to address sensory processing impairments in older adults with dementia. [WATCH TIME: 5 minutes]

At AAIC 2026, the senior research professor of neurology at Indiana University School of Medicine discussed the evolving role of blood-based Alzheimer disease biomarkers, particularly p-tau217.

At AAIC 2026, professor of neurology at Washington University in St. Louis discussed how integrating clinical assessment with amyloid biomarkers can improve diagnostic accuracy in Alzheimer disease. [WATCH TIME: 5 minutes]

The 60 mg dose showed the largest treatment effect, slowing decline by 26% on CDR-SB, 42% on ADAS-Cog13, and 50% on MMSE at 18 months, while all doses produced 50% to 65% reductions in CSF total tau and unprecedented tau PET reductions across brain regions.

At AAIC 2026, associate professor of neurology at Albert Einstein College of Medicine discussed a culinary medicine intervention to improve MIND diet adherence and mood in older adults with type 2 diabetes. [WATCH TIME: 5 minutes]

MCLENA-1 enrolled only 6 completers due to funding constraints but demonstrated 12 months of continuous lenalidomide was safe and tolerable, with nonsignificant trends favoring treatment on cognition and global outcomes.

A new phase 2 trial, presented at AAIC 2026, aims to evaluate the effects of urolithin A on mitophagy/autophagy activity, oxidative stress, multi-omic profiling, and cognitive function in APOE4 carriers.